Screening for Pancreatic Cancer in Adults at High Risk Due to Family History or Genetic Conditions

What this Trial Is About

Pancreatic ductal adenocarcinoma PDAC is a cancer with one of the worst prognoses, mainly due to its late diagnosis and rapid progression. In the Czech Republic, the incidence of this cancer has been increasing, with a very low overall five-year survival rate between 7-9%. Early detection is challenging because symptoms are often absent or non-specific, and current screening methods are limited. This trial focuses on screening individuals at high risk for pancreatic cancer, aiming to improve early diagnosis and potentially increase the chances of curative treatment. The study evaluates different screening methods including endoscopic ultrasonography, magnetic resonance imaging, and laboratory tests such as blood markers related to pancreatic health. Participants are grouped based on their risk factors, such as chronic pancreatitis, specific genetic mutations linked to hereditary syndromes, or a family history of pancreatic cancer. Screening frequency varies by group and is planned for up to 60 months, with annual monitoring through the specified procedures. Participants in the study will undergo regular imaging and laboratory examinations to detect pancreatic cancer early. Researchers will track the number of new pancreatic cancer cases diagnosed during the study and compare the effectiveness and cost-efficiency of the screening methods. They will also evaluate the presence of certain genetic mutations over time. The study includes ongoing monitoring to ensure participants can undergo the necessary imaging and potential surgery if needed. The total participation time can extend up to five years.

Pancreatic Cancer Screening in a Population at High Risk